CA2511966A1 - Modulateurs de recepteurs de l'hormone parathyroide et de la proteine liee a l'hormone parathyroide - Google Patents

Modulateurs de recepteurs de l'hormone parathyroide et de la proteine liee a l'hormone parathyroide Download PDF

Info

Publication number
CA2511966A1
CA2511966A1 CA002511966A CA2511966A CA2511966A1 CA 2511966 A1 CA2511966 A1 CA 2511966A1 CA 002511966 A CA002511966 A CA 002511966A CA 2511966 A CA2511966 A CA 2511966A CA 2511966 A1 CA2511966 A1 CA 2511966A1
Authority
CA
Canada
Prior art keywords
residue
nonfunctional
pth
composition
matter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002511966A
Other languages
English (en)
Inventor
Paul Kostenuik
Colin V. Gegg
Mark Anthony Jarosinski
Olaf Boris Kinstler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2511966A1 publication Critical patent/CA2511966A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à des agents thérapeutiques qui modulent l'activité de PTH et de PTHrP. Conformément à l'invention, les modulateurs de PTH et de PTHrP contiennent : (a) un domaine modulateur de PTH/PTHrP ; et (b) un véhicule, tel qu'un polymère (par ex., PEG ou dextrane) ou de préférence un domaine Fc ; le véhicule étant lié par covalence au terminus C du domaine modulateur de PTH/PTHrP ou par l'intermédiaire d'une chaîne latérale au niveau d'un résidu quelconque du résidu 14 au résidu C-terminal. Le véhicule et le domaine modulateur de PTH/PTHrP peuvent être liés par l'intermédiaire du terminus N ou C du domaine modulateur de PTH/PTHrP, comme le précise le descriptif de l'invention. Le véhicule préféré est PEG. Les domaines modulateurs de PTH/PTHrP préférés contiennent les séquences d'acides aminés dérivées de PTH et de PTHrP définies dans le descriptif de l'invention. D'autres domaines modulateurs de PTH/PTHrP peuvent être générés par expression phagique, par criblage d'ARN-peptide et par les autres techniques mentionnées dans le descriptif. De tels peptides sont en général des modulateurs de l'activité tant PTH que PTHrP, même si lesdites techniques peuvent servir à générer des séquences peptidiques qui jouent le rôle de modulateurs sélectifs (par ex., d'agonistes de l'activité PTH mais non de l'activité PTHrP).
CA002511966A 2002-11-01 2002-11-01 Modulateurs de recepteurs de l'hormone parathyroide et de la proteine liee a l'hormone parathyroide Abandoned CA2511966A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/036419 WO2004060386A1 (fr) 2002-11-01 2002-11-01 Modulateurs de recepteurs de l'hormone parathyroide et de la proteine liee a l'hormone parathyroide

Publications (1)

Publication Number Publication Date
CA2511966A1 true CA2511966A1 (fr) 2004-07-22

Family

ID=32710245

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002511966A Abandoned CA2511966A1 (fr) 2002-11-01 2002-11-01 Modulateurs de recepteurs de l'hormone parathyroide et de la proteine liee a l'hormone parathyroide

Country Status (4)

Country Link
EP (1) EP1567178A4 (fr)
AU (1) AU2002359391A1 (fr)
CA (1) CA2511966A1 (fr)
WO (1) WO2004060386A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2006135930A2 (fr) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Administration transmucosale de dérivés peptidiques
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
EP2574624A1 (fr) 2006-04-20 2013-04-03 Amgen Inc. Composés GLP-1
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2008063279A2 (fr) 2006-10-03 2008-05-29 Radius Health, Inc. Procédé d'administration pharmacologique d'une protéine anabolique osseuse
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
WO2008048784A1 (fr) 2006-10-13 2008-04-24 Eli Lilly And Company PHT pégylés en tant que modulateurs du récepteur PHT et leurs utilisations
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
AU2014229563B2 (en) 2013-03-15 2020-04-09 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of cancer metastasis
JP7019422B2 (ja) 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
CN117417263A (zh) 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
KR20210030393A (ko) 2018-07-04 2021-03-17 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2807892A (en) * 1991-10-10 1993-05-03 Peter K.T. Pang Parathyroid hormone analogues and use in osteoporosis treatment
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
JP4122061B2 (ja) * 1996-08-02 2008-07-23 ナショナル リサーチ カウンシル オブ カナダ 骨粗鬆症の治寮のための副甲状腺ホルモン類似体
AU1633200A (en) * 1998-11-25 2000-06-13 General Hospital Corporation, The Human parathyroid hormone modifications, preparation and use
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
JP2004536571A (ja) * 2001-02-21 2004-12-09 クローンテック ラボラトリーズ インク． 非凝集性蛍光性タンパク質およびその使用方法

Also Published As

Publication number Publication date
EP1567178A4 (fr) 2009-07-15
AU2002359391A1 (en) 2004-07-29
WO2004060386A1 (fr) 2004-07-22
EP1567178A1 (fr) 2005-08-31

Similar Documents

Publication Publication Date Title
AU2001257321B2 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
US20050124537A1 (en) Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2001257321A1 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
US6677136B2 (en) Glucagon antagonists
US7919118B2 (en) Spacer moiety for poly (ethylene glycol) modified peptide based compounds
AU2001257173B2 (en) Apo-ai/aii peptide derivatives
CA2511966A1 (fr) Modulateurs de recepteurs de l'hormone parathyroide et de la proteine liee a l'hormone parathyroide
CA2349406C (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
AU2001257173A1 (en) Apo-AI/AII peptide derivatives
US20020090646A1 (en) Calcitonin-related molecules
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
AU2005237128B2 (en) Compositions and Methods for the Prevention or Treatment of Cancer and Bone Loss Associated with Cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued